UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 HEARTSCIENCES INC. (Exact name of Registrant as Specified in Its Charter) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commen ...

Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2025 ended January 31, 2025 and provided a business update. Third Fiscal Quarter 2025 Highlights: During the third quarter of fiscal year 2025 (“Q3 FY2025”) and t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41422 HEARTSCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Securities registered pursuant to Section 12(b) of the Act: | | Trading | | | --- ...

Southlake, TX, March 10, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has engaged Integrous Communications, a premier investor relations firm, to enhance communication channels with investors and the investment community. Under the expert guidance of Integrous Communica ...

Financial Performance - HeartSciences Inc. reported financial results for the quarter ended October 31, 2024, with total revenue of $2.5 million, representing a 25% increase year-over-year[10] - The company achieved a gross margin of 60% for the quarter, up from 55% in the same period last year[10] - Operating expenses for the quarter were $1.8 million, a 10% increase compared to the previous year, primarily due to R&D investments[10] - HeartSciences reported a net loss of $500,000 for the quarter, an improvement from a net loss of $700,000 in the same quarter last year[10] User Growth - User data indicated a 30% increase in the number of active users, reaching 15,000 by the end of the quarter[10] Future Outlook - HeartSciences provided an optimistic outlook, projecting revenue growth of 20-25% for the next quarter[10] - The company is currently developing a new cardiac monitoring device expected to launch in Q2 2025[10] - HeartSciences plans to expand its market presence in Europe, targeting a 15% market share by the end of 2025[10] Strategic Initiatives - The company is exploring potential acquisition opportunities to enhance its product portfolio and market reach[10] - The company emphasized its commitment to innovation and strategic partnerships to drive future growth[10]

Core Insights - HeartSciences Inc. is focused on transforming ECG technology through AI to enhance early detection of heart disease and has reported significant progress in its business and technology developments for Q2 FY2025 [1][2] Business Highlights - HeartSciences is the only company developing next-generation ECG device hardware, cloud-native software, and AI-ECG algorithms, aiming to modernize the ECG industry which relies on outdated technology [2][11] - The MyoVista Insights platform is nearing completion of Phase 1, with a focus on creating a cloud-native ECG reporting system on AWS, expected to be implemented in test sites in the first half of 2025 [3][4] - Phase 2 will introduce AI-ECG reporting and operate like an app store for AI-ECG algorithms, reducing costs and regulatory burdens [4][5] - Phase 3 aims to establish an ECG management system, targeting a multi-billion dollar market, with a focus on lower costs and improved interoperability [5] Product Development - Progress on the MyoVista® wavECG device is on track for FDA submission by the end of Q1 2025, with a pre-submission meeting planned to finalize the validation study [7] - The first cloud-based AI-ECG algorithm, focusing on low ejection fraction, is in pre-validation, with FDA validation studies anticipated to follow [6] Regulatory and Market Position - HeartSciences' AI-ECG algorithms have been included in the CMS 2025 OPPS final rule, allowing for immediate reimbursement upon commercial launch, marking a significant milestone for AI-ECG adoption [8] - The company aims to provide a versatile AI-ECG solution suitable for various healthcare settings, enhancing access to cardiac screening tools [11][13] Financial Overview - For Q2 FY2025, HeartSciences reported no revenues, with cash and cash equivalents at approximately $4.1 million and shareholders' equity at approximately $4.0 million [12]

Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that Company CEO Andrew Simpson has been invited to participate in the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC and hosted by M-Vest, from Tuesday October ...

Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update. First Fiscal Quarter 2025 Highlights: During the first quarter of fiscal yea ...

AI Technology Development - The company is focused on developing AI-based ECG technology to enhance cardiac screening capabilities [106]. - The MyoVista wavECG device is a proprietary 12-lead ECG that integrates AI-ECG algorithms for improved diagnostic information [106]. - The company entered into License Agreements with Mount Sinai to commercialize AI-ECG algorithms for various cardiovascular conditions [108]. - The FDA has cleared an algorithm for low ejection fraction (less than 40%) under the 510(k) pathway, with a submission for the MyoVista wavECG device planned for Q1 2025 [115]. - The company has received a patent for MyoVista wavelet technology from the Indian Patent Office in May 2024 [122]. Financial Performance - The company incurred approximately $300,000 in accrued interest to FRV as part of a debt extension agreement [122]. - The Streeterville Note issued to the company amounts to $2,510,000, with an interest rate of 8.5% per annum and a maturity of 18 months [123]. - Operating expenses primarily consist of research and development and selling, general, and administrative expenses [125]. - Research and development expenses include costs related to clinical trials, regulatory compliance, and personnel-related costs [126]. - Research and development expenses increased to $1.2 million for the three months ended July 31, 2024, up by $659,000 or 117% compared to the same period in 2023, primarily due to consulting costs for the MyoVista Insights Cloud Platform [129]. - Selling, general, and administrative expenses were approximately $0.9 million for the three months ended July 31, 2024, an increase of $86,000 or 11% compared to the same period in 2023, mainly due to payroll and professional expenses related to the reverse stock split [129]. - Total operating expenses reached $2.1 million for the three months ended July 31, 2024, reflecting a $745,000 or 56% increase from $1.3 million in the same period of 2023 [128]. - The net loss for the period ended July 31, 2024, was $2.1 million, a $685,000 or 50% increase compared to a net loss of $1.4 million in the same period of 2023 [128]. - As of July 31, 2024, the company had an accumulated deficit of $69.4 million and stockholder's equity of $5.9 million, with working capital of $4.7 million [131]. - The company incurred net cash used in operating activities of $2.0 million for the three months ended July 31, 2024, compared to $1.4 million for the same period in 2023 [137]. Capital Raising Activities - The company raised approximately $1.6 million from the sale of Common Stock under the Lincoln Park Purchase Agreement as of the date of the Quarterly Report [132]. - The company received approximately $9.8 million in net proceeds from the sale of Common Stock under the amended EDA as of the date of the Quarterly Report [133]. - The company entered into a Note Purchase Agreement with Streeterville for an unsecured promissory note of $2.51 million, resulting in approximately $1.9 million in net cash proceeds [134]. - The company reported a decrease in cash and cash equivalents to approximately $4.3 million as of July 31, 2024, down from $5.8 million as of April 30, 2024 [135].

Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the close of a non-dilutive financing, with $1.9 million in net proceeds. The unsecured loan note has an 18-month maturity date and follows the recent 12-month extension of a $500 ...